Please log in
to access more information

loading...

User name and Password not recognised

Home Page > News > SEPTEMBER 13TH, 2018

SEPTEMBER 13TH, 2018

H1 2018 RESULTS
ON TRACK WITH THE COMPANY’S BUSINESS PLAN 

▪ €41 million raised through a capital increase and an OBSA bond issue

▪ Successful implementation of commercial infrastructures in the United States

▪ Reinforced management team

Saint-Priest, France, September 13, 2018 – 8:00 CEST – Pursuant to the adoption of the interim consolidated financial statements for the period ended June 30, 2018 by the Board of Directors on September 12, 2018, Biom’up (the "Company"), specialist of surgical hemostasis, today announces its first-half results.

The statutory auditors have performed a limited review of the consolidated financial statements adopted by the Board of Directors on September 12, 2018.

Etienne Binant, Chief Executive Officer of Biom’up, commented: "Biom’up has made significant progress since its successful IPO in October 2017. The two financing deals completed at the start of the year, i.e. the capital increase through a public offering and the bond issue with stock warrants attached, have allowed the Company to raise €41 million since the IPO, thus ensuring we have the resources to match our ambitions over the medium-term. The first half results published today reflect our efforts of the last six months, focused on financing, increased production capacity and the successful implementation of our commercial infrastructure in the United States. The remainder of the year will be focused on launching the construction of the second manufacturing facility near Saint-Priest, the expansion of the hemostatic line with continuing studies required for HEMOBLASTTM Bellows and HemosnowTM and, of course, the commercial launch of our lead product in the United States". 

» Biomup_-_PR_RFS_2018_VO_4134-9267-7399_2_c79b7.pdf